Wosulin R Dispopen 2 contains Human insulin at a concentration of 100 IU/ml, formulated for the management of diabetes mellitus requiring insulin therapy. This rapid-acting insulin is identical to endogenous human insulin and functions by facilitating cellular glucose uptake, thereby reducing blood glucose levels. Wosulin R Dispopen 2 is indicated for patients with type 1 diabetes mellitus and for some patients with type 2 diabetes mellitus when oral hypoglycemic agents alone do not provide adequate glycemic control. The product is supplied in a ready-to-use disposable pen device, allowing for accurate dosing and ease of administration. It is typically administered subcutaneously 30 minutes before meals to optimize postprandial glucose control, with dosing individualized based on the patient’s metabolic needs, blood glucose monitoring results, and lifestyle. Careful titration is essential to minimize the risk of hypoglycemia, the most common adverse effect associated with insulin therapy. Wosulin R Dispopen 2 should be stored under recommended conditions to maintain potency. Patients should be educated on proper injection techniques, dose adjustment, and recognition of hypoglycemia symptoms. This insulin product should be used under medical supervision as part of a comprehensive diabetes management plan.